摘要
目的探讨溶血磷脂酸(lysophosphatidic acid,LPA)对子宫内膜癌RL-952细胞尿激酶型纤溶酶原激活剂(urokinase-type plasminogen activator,uPA)分泌的影响。方法不同浓度的LPA刺激子宫内膜癌RL-952细胞24h,80μmol/LLPA刺激子宫内膜癌RL-952细胞不同时间后收集细胞上清液,采用酶联免疫吸附试验检测uPA的分泌情况,Transwell试验检测LPA对子宫内膜癌RL-952细胞体外迁移/侵袭能力的影响。结果 2、10μmol/L的LPA即可诱导子宫内膜癌RL-952细胞uPA的分泌增加,且随着LPA浓度的加大,uPA分泌量明显增多,二者呈明显的浓度依赖关系;80μmol/L的LPA作用于RL-952细胞时,随着时间的延长uPA分泌量增多,二者呈明显的时间依赖关系。并且LPA可以明显增加子宫内膜癌RL-952细胞的体外迁移/侵袭能力。结论 LPA可成为子宫内膜癌早期诊断及预后监测的分子标志物,并有望成为子宫内膜癌分子靶向治疗的靶标。
Objective To investigate the effect of urokinase-type plasminogen activator(uPA) secretion on endometrial carcinoma RL-952cell by stimulating of lysophosphatidic acid(LPA).Methods Supernatant of endo-metrial carcinoma RL-952 cells was collected after stimulating with determined concentrations of LPA for 24hours or with 80μmol/L LPA at determined times,levels of urokinase-type plasminogen activator(uPA)in these super-natant were determined by enzyme labeled immunosorbent assay(ELISA).Transwell chamber assay was used to detect the migration/invasion abilities.Results 2μmol/L,10μmol/L concentrations of LPA can induce uPA secretion,and with the concentration increasing,the uPA production increased significantly which showed obvious con-centration-dependent,and also it showed significant time-dependent.The LPA significantly increased the migration/ invasion of endometrial cancer RL-952cells.Conclusions LPA is expected to become the molecular markers,the LPA receptor and its signaling pathway is expected to become the target of the molecular therapy of endometrial cancer.
出处
《中国妇产科临床杂志》
2012年第4期291-293,共3页
Chinese Journal of Clinical Obstetrics and Gynecology
基金
国家自然基金(C30973181)
关键词
溶血磷脂酸
子宫内膜癌
尿激酶型纤溶酶原激活剂
酶联免疫吸附试验
分子靶向治疗
lysophosphatidic acid; endometrial carcinoma; urokinase-type plasminogen activator; enzyme-linked immunosorbent assay; molecular targeted therapy